Free Trial
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$3.24 +0.05 (+1.41%)
Closing price 07/3/2025 03:14 PM Eastern
Extended Trading
$3.24 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Key Stats

Today's Range
$3.19
$3.28
50-Day Range
$3.08
$3.61
52-Week Range
$2.71
$4.73
Volume
354,262 shs
Average Volume
959,904 shs
Market Capitalization
$619.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

ABUS MarketRank™: 

Arbutus Biopharma scored higher than 33% of companies evaluated by MarketBeat, and ranked 2293rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arbutus Biopharma has received no research coverage in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 6.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arbutus Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.41% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 0.71%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.41% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 0.71%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Arbutus Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus Biopharma Corporation (ABUS) - Yahoo Finance
Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $3.27 on January 1st, 2025. Since then, ABUS shares have decreased by 1.1% and is now trading at $3.2350.

Arbutus Biopharma Corporation (NASDAQ:ABUS) released its earnings results on Wednesday, May, 14th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.54 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 75.51% and a negative net margin of 1,196.64%.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/14/2025
Today
7/04/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABUS
Employees
90
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+70.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.92 million
Net Margins
-1,196.64%
Pretax Margin
-1,195.86%

Debt

Sales & Book Value

Annual Sales
$6.17 million
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
6.34

Miscellaneous

Free Float
152,647,000
Market Cap
$619.60 million
Optionable
Optionable
Beta
1.20

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners